Expertise in
6
conditions

Dr. Matthew J. Zirwas

Dermatology
Dermatologists Of Southwestern Ohio, LLC
2359 E Main St, 
Bexley, OH 
Accepting New Patients
Expertise in
6
conditions
Dermatologists Of Southwestern Ohio, LLC
2359 E Main St, 
Bexley, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Zirwas is a Dermatologist in Bexley, Ohio. Dr. Zirwas is highly rated in 6 conditions, according to our data. His top areas of expertise are Contact Dermatitis, Atopic Dermatitis, Plaque Psoriasis, and Psoriasis. Dr. Zirwas is currently accepting new patients.

His clinical research consists of co-authoring 143 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

DERMATOLOGISTS OF SOUTHWESTERN OHIO, LLC
2359 E Main St, Bexley, OH 43209
Other Locations
DERMATOLOGISTS OF SOUTHWESTERN OHIO, LLC
5300 Far Hills Ave, Dayton, OH 45429

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

143 Total Publications

Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis.
Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis.
Journal: Journal of drugs in dermatology : JDD
Published: May 06, 2025
Similar Doctors
Expertise in
28
conditions
Dr. Benjamin H. Kaffenberger
Dermatology
Expertise in
28
conditions
Dr. Benjamin H. Kaffenberger
Dermatology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
 (5.1 mi)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Kaffenberger is a Dermatologist in Columbus, Ohio. Dr. Kaffenberger is highly rated in 28 conditions, according to our data. His top areas of expertise are Pyoderma Gangrenosum, Cellulitis, DRESS Syndrome, Erythema Multiforme, and Tissue Biopsy. Dr. Kaffenberger is currently accepting new patients.

Expertise in
25
conditions
Dr. Catherine G. Chung
Dermatology
Expertise in
25
conditions
Dr. Catherine G. Chung
Dermatology

Osu Internal Medicine LLC

540 Officenter Pl, Suite 240, 
Gahanna, OH 
 (5.2 mi)
614-293-1707
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Catherine Chung is a Dermatologist in Gahanna, Ohio. Dr. Chung is highly rated in 25 conditions, according to our data. Her top areas of expertise are Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Lymphomatoid Papulosis, and Tissue Biopsy. Dr. Chung is currently accepting new patients.

Expertise in
4
conditions
Dr. Susan T. Nedorost
Dermatology
Expertise in
4
conditions
Dr. Susan T. Nedorost
Dermatology

Dermatologists Of Southwestern Ohio, LLC

2359 E Main St, 
Bexley, OH 
 (0.1 mi)
614-947-1716
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Susan Nedorost is a Dermatologist in Bexley, Ohio. Dr. Nedorost is highly rated in 4 conditions, according to our data. Her top areas of expertise are Stasis Dermatitis and Ulcers, Contact Dermatitis, Atopic Dermatitis, and Papular Urticaria. Dr. Nedorost is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zirwas's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile